Drug intelligence / Profile preview

gemcitabine + carboplatin + nivolumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of gemcitabine (a nucleoside analog), carboplatin (a platinum-based chemotherapy agent), and nivolumab (an immune checkpoint inhibitor). The combination is being investigated for the treatment of various cancers, including urothelial cancer and non-small cell lung cancer (NSCLC). Nivolumab is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody that blocks the interaction between PD-1 receptors on T cells and PD ligands 1 and 2 (PD-L1/PD-L2), restoring T-cell antitumor function.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on gemcitabine + carboplatin + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + carboplatin + nivolumab.

Explore the full profile